Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Clinical trial NCT05985655 · RECRUITING

Trial details

NCT number: NCT05985655
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma Triple Negative Breast Cancer (TNBC)

Start date: 2023-07-06
Primary completion: 2028-01-01
Enrollment: 230

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.